Asset profile
AB-1005
Gene therapy / editing
Evidence outlook · lead readout
NCT01621581 · Parkinson's Disease
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT01621581: This was a single-arm, open-label study with no control group and no blinding, so any apparent benefit cannot be separated from the natural course of the disease or a placebo response, and no results have been posted yet.
The long-term imaging analysis covers the 13 participants who received the study infusion, fewer than the number recorded as enrolled in the registry.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
April 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAugust 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (1)
June 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.